Dec 02 2022

President Biden Signs Medical Marijuana and Cannabidiol Research Expansion Act Into Law

President Biden has officially signed the Medical Marijuana and Cannabidiol Research Expansion Act into law, making it the first standalone piece of marijuana legislation to ever be signed into law by a U.S. president.

H.R. 8454 was signed into law today by President Biden, a little over two weeks after it passed the Senate. It passed the House of Representatives in July.

“Thank you to Representatives Blumenauer, Harris, Griffith, Joyce, Mace, and Perlmutter, Delegate Norton, and Senators Feinstein, Grassley, Schatz, Durbin, Klobuchar, Tillis, Kaine, Ernst, Tester, and Murkowski for their leadership”, President Biden said in a statement following signage of the bill.
Continue reading

Dec 01 2022

Study: THC and CBN Induced Cell Death in Cholangiocarcinoma (Bile Duct Cancer)

According to a new peer-reviewed study the cannabis compounds THC and CBN (cannabinol) induced apoptosis (cell death) in an animal model of cholangiocarcinoma (bile duct cancer).

The study was published in the journal Evidence-Based Complementary and Alternative Medicine, and was conducted by researchers at Rangsit University, Bumrungrad International Hospital and Thammasat University, all in Thailand.

As noted by the study, cholangiocarcinoma (CCA) is a very aggressive tumor. Although it’s rare worldwide, it is one of the most common cancers in northeast Thailand. Given it’s highly resistant to chemotherapy, “the development of a new therapeutic drug for CCA is required.”

This study aimed “to evaluate the antitumor effect of ∆9-tetrahydrocannabinol (THC), the major psychoactive component of marijuana (Cannabis sativa), and cannabinol (CBN), a minor, low-psychoactive cannabinoid, on CCA cells and xenograft mice.”
Continue reading

Dec 01 2022

Legal Marijuana Sales Now Underway in Rhode Island

Legal marijuana sales are now taking place in Rhode Island for the first time.

Although just five retail marijuana outlets opened their doors today in Rhode Island, that number is expected to grow to 33 in the coming months.

The five outlets currently opened are:

  • Aura of Rhode Island (Central Falls)
  • Thomas C. Slater Center (Providence)
  • Mother Earth Wellness (Pawtucket)
  • Greenleaf Compassionate Care Center (Portsmouth)
  • RISE Warwick (Warwick)

Continue reading

Nov 30 2022

Poll: U.S. Adults Support Ending Federal Marijuana Ban by a 50-Point Margin

According to a new Data for Progress poll, 74% of American adults support ending the federal ban on marijuana, with just 24% opposed to the idea.

Support for ending the nation’s ban on marijuana was highest among Democrats at 81%, but there was still widespread support among Independents (76%) and Republicans (65%).

Of those who support ending marijuana prohibition, 47% “strongly support” the move, while 27% “somewhat support” it. For those opposed, it’s split 12% to 12% among those who “strongly oppose” it and those who “somewhat oppose” it. Just 4% remain undecided.
Continue reading

Nov 29 2022

D.C. Council Committee Votes to Significantly Expand Medical Marijuana Law

The Washington D.C. Committee on Business and Economic Development has passed legislation to expand the district’s medical marijuana law.

The proposal, which now goes to the D.C. Committee of the Whole, would make several changes to liberalized the district’s medical marijuana program. This includes eliminating the cap on marijuana businesses (allowing the free market, rather than an arbitrary cap, to decide the number of marijuana stores in the district) and creating new business categories within the industry including on-site consumption facilities and marijuana cooking classes.

Possibly the biggest change would allow medical marijuana patients to self-certify that they’re qualified to purchase, possess and use medical marijuana and marijuana products.
Continue reading

Nov 29 2022

California has Garnered $4.4 Billion in Marijuana Taxes Since Legal Sales Began in 2018

Legal recreational marijuana sales began in Q1, 2018 in California, and since that period the state has garnered billions in new tax revenue.

According to data released by the California Department of Tax and Fee Administration, there has been $19,262,487,673 in marijuana and marijuana products sold between Q1, 2018 and Q3, 2022. This has resulted in $4,397,112,676 in new tax revenue for the state.

A slight majority of this tax revenue came from the state’s excise tax on marijuana, followed by revenue earned from the state’s standard sales tax. A smaller, but still considerable portion of the revenue was garnered from California’s marijuana cultivation tax.
Continue reading

Nov 28 2022

Study: CBD has Direct Antineoplastic Effects on Lung Cancer Cells

Cannabidiol (CBD) has “direct antineoplastic [cancer treating] effects on lung cancer cells”, according to a new study being published in the upcoming issue of the Iranian Biomedical Journal.

The study was epublished ahead of print on the website for the U.S. National Institute of Health.

“Lung cancer remains a major factor contributing to morbidity and mortality worldwide”, states the study’s abstract. “Apart from the chemotherapeutic agents in routine use, factors targeting novel molecular pathways are in clinical trials and provide hope for terminal lung cancer patients.”

Researchers note that the endocannabinoid system has recently become a popular field of study, with many experimental studies showing that CBD and THC could be used outside of palliative care, as they play a major role in lung cancer cell apoptosis. The objective of this study was to “evaluate the antitumorigenic mechanisms of CBD in lung cancer cells.”
Continue reading

Nov 27 2022

Report: Market for Cannabis Infused Products to Grow from $29 Billion to $150 Billion by 2030

According to a new Cannabis Infused Products Market report, the market is currently valued at $29.68 billion and is expected to grow at an incredible rate to reach a value of $150.1 billion by 2030.

Data Bridge Market Research analyses that the cannabis infused products market which was USD 29.68 billion in 2022, would rocket up to USD 150.51 billion by 2030, and is expected to undergo a compound annual growth rate (CAGR) of 22.5% during the forecast period 2023 to 2030.

According to the report, the cannabis infused products market is expected to witness significant growth during the forecast period of 2023-2030. The increasing number of scientific trials of cannabis-infused medications for various therapeutic areas, particularly cannabidiol use, is driving market growth. Furthermore, the narrative among physicians about the benefits of cannabis-infused medicines, as well as supporting clinical evidence, is leading to an increase in patient prescriptions for cannabis-infused medicines.
Continue reading

Nov 27 2022

South Dakota Marijuana Legalization Proponents Vow to Put New Initiative on 2024 Ballot

Proponents of legalizing marijuana in South Dakota have vowed to once again put a legalization initiative on the ballot, this time during the 2024 general election.

South Dakotans for Better Marijuana Laws was successful in getting marijuana initiatives on the ballot in 2020 and 2022. In 2020 voters approved the initiative, though it was later struck down by the courts due to a technicality. In 2022, mainly due to low turnout, the initiative was defeated although 47% did vote in favor. Now the group is hoping third times a charm, and are aiming to put the issue to a vote in 2024, says campaign director Matthew Schweich.

Schweich says the initiative will be based on this year’s Measure 27, which would have legalized the possession and purchase (from a licensed retail outlet) of up to an ounce of marijuana, for those 21 and older, while also allowing them to grow a few plants for personal use.
Continue reading

Nov 25 2022

Study: CBD Reduces Seizures That Are Resistant to Common Medications

A new study has found that CBD reduces seizures in patients with Dravet syndrome (SD), Lennox-Gataut syndrome (LGS), or tuberous sclerosis complex (TSC), who are resistant to common medications.

Published by the journal Revista da Associação Médica Brasileira and epublished by the National Library of Medicine, the study was conducted by researchers at Medicina Baseada em Evidências and Faculdade de Medicina, both in Brasil.

According to its abstract, the objective of this “systematic review with meta-analysis was to evaluate the efficacy, safety, and short- and long-term tolerability of cannabidiol (CBD), as an adjunct treatment, in children and adults with Dravet syndrome (SD), Lennox-Gataut syndrome (LGS), or tuberous sclerosis complex (TSC), with inadequate control of seizures.”
Continue reading